Benefits and risks of popular weight-loss drugs revealed

Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study reporting one in eight Americans has taken or is currently using the drugs to treat diabetes, heart disease or obesity.

Former Seagen CEO David Epstein to lead new biotech with VEGF bifunctional antibody

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

October 29, 2024

Tebentafusp’s OS Benefit in Uveal Melanoma Holds Up at 3 Years

MADRID — The significant survival benefit with the bispecific T-cell receptor therapy tebentafusp (Kimmtrak) held up at 3 years for selected patients with previously untreated

October 22, 2023

Awakn Life Sciences Completes Successful Investigative Study to Establish Dissociative Effect of a Proprietary Sublingual S-Ketamine Oral Thin Film Formulation in Harmful Drinkers | Psychedelic Invest

Awakn Life Sciences Corp. (CBOE: AWKN) (OTCQB: AWKNF) (FSE: 954) (“Awakn”), a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a near-term focus on

January 24, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.